Compile Data Set for Download or QSAR
Report error Found 270 Enz. Inhib. hit(s) with all data for entry = 10184
TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450307(US10676431, Example 70 | US11117861, Example 70)
Affinity DataEC50:  0.0770nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450267(US10676431, Example 30 | US11117861, Example 30)
Affinity DataEC50:  0.220nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450349(US10676431, Example 112 | US11117861, Example 112)
Affinity DataEC50:  0.270nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450358(US10676431, Example 121 | US10676431, Example 122 ...)
Affinity DataEC50:  0.300nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450350(US10676431, Example 113 | US11117861, Example 113)
Affinity DataEC50:  0.390nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450320(US10676431, Example 83 | US11117861, Example 83)
Affinity DataEC50:  0.410nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450236(US10676431, Example 1 | US11117861, Example 1)
Affinity DataEC50:  0.430nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450346(US10676431, Example 109 | US11117861, Example 109)
Affinity DataEC50:  0.440nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450369(US10676431, Example 132 | US11117861, Example 132)
Affinity DataEC50:  0.480nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450264(US10676431, Example 27 | US11117861, Example 27)
Affinity DataEC50:  0.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450318(US10676431, Example 81 | US11117861, Example 81)
Affinity DataEC50:  0.520nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450305(US10676431, Example 68 | US11117861, Example 68)
Affinity DataEC50:  0.530nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450262(US10676431, Example 25 | US11117861, Example 25)
Affinity DataEC50:  0.530nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450263(US10676431, Example 26 | US11117861, Example 26)
Affinity DataEC50:  0.550nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450340(US10676431, Example 103 | US11117861, Example 103)
Affinity DataEC50:  0.570nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450276(US10676431, Example 39 | US11117861, Example 39)
Affinity DataEC50:  0.580nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450309(US10676431, Example 72 | US11117861, Example 72)
Affinity DataEC50:  0.610nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450322(US10676431, Example 85 | US11117861, Example 85)
Affinity DataEC50:  0.620nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450338(US10676431, Example 101 | US11117861, Example 101)
Affinity DataEC50:  0.660nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450240(US10676431, Example 5 | US11117861, Example 5)
Affinity DataEC50:  0.680nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450357(US10676431, Example 120 | US10676431, Example 128 ...)
Affinity DataEC50:  0.780nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450361(US10676431, Example 124 | US11117861, Example 124)
Affinity DataEC50:  0.790nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450336(US10676431, Example 99 | US11117861, Example 99)
Affinity DataEC50:  0.790nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450358(US10676431, Example 121 | US10676431, Example 122 ...)
Affinity DataEC50:  0.810nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450323(US10676431, Example 86 | US11117861, Example 86)
Affinity DataEC50:  0.850nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450351(US10676431, Example 114 | US11117861, Example 114)
Affinity DataEC50:  0.860nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450310(US10676431, Example 73 | US11117861, Example 73)
Affinity DataEC50:  0.890nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450269(US10676431, Example 32 | US11117861, Example 32)
Affinity DataEC50:  0.910nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450239(US10676431, Example 4 | US11117861, Example 4)
Affinity DataEC50:  0.930nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450294(US10676431, Example 57 | US11117861, Example 57)
Affinity DataEC50:  0.950nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450362(US10676431, Example 125 | US10676431, Example 127 ...)
Affinity DataEC50:  0.990nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450320(US10676431, Example 83 | US11117861, Example 83)
Affinity DataEC50:  0.990nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450241(US10676431, Example 6 | US11117861, Example 6)
Affinity DataEC50:  1nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450357(US10676431, Example 120 | US10676431, Example 128 ...)
Affinity DataEC50:  1nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450279(US10676431, Example 42 | US11117861, Example 42)
Affinity DataEC50:  1nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450338(US10676431, Example 101 | US11117861, Example 101)
Affinity DataEC50:  1.10nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450347(US10676431, Example 110 | US11117861, Example 110)
Affinity DataEC50:  1.10nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450270(US10676431, Example 33 | US11117861, Example 33)
Affinity DataEC50:  1.10nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450238(US10676431, Example 3 | US11117861, Example 3)
Affinity DataEC50:  1.10nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450314(US10676431, Example 77 | US11117861, Example 77)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450315(US10676431, Example 78 | US11117861, Example 78)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450324(US10676431, Example 87 | US11117861, Example 87)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450302(US10676431, Example 65 | US11117861, Example 65)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450352(US10676431, Example 115 | US10676431, Example 116 ...)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450368(US10676431, Example 131 | US11117861, Example 131)
Affinity DataEC50:  1.20nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450352(US10676431, Example 115 | US10676431, Example 116 ...)
Affinity DataEC50:  1.21nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450345(US10676431, Example 108 | US11117861, Example 108)
Affinity DataEC50:  1.40nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450274(US10676431, Example 37 | US11117861, Example 37)
Affinity DataEC50:  1.40nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450317(US10676431, Example 80 | US11117861, Example 80)
Affinity DataEC50:  1.40nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM450360(US10676431, Example 123 | US11117861, Example 123)
Affinity DataEC50:  1.5nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays. A mixture of forskolin (5 μM final for FPR2 or 10 μM final for FPR1) and IBMX (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2022
Entry Details
US Patent

Displayed 1 to 50 (of 270 total ) | Next | Last >>
Jump to: